About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 230805, 18 pages
http://dx.doi.org/10.1155/2013/230805
Review Article

Extracellular Matrix Degradation and Tissue Remodeling in Periprosthetic Loosening and Osteolysis: Focus on Matrix Metalloproteinases, Their Endogenous Tissue Inhibitors, and the Proteasome

1Department of Anatomy, Histology, Embryology, Medical School, University of Patras, 26500 Patras, Greece
2Laboratory of Biochemistry, Department of Chemistry, University of Patras, 26500 Patras, Greece

Received 30 April 2013; Accepted 31 May 2013

Academic Editor: Achilleas D. Theocharis

Copyright © 2013 Spyros A. Syggelos et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Sundfeldt, L. V. Carlsson, C. B. Johansson, P. Thomsen, and C. Gretzer, “Aseptic loosening, not only a question of wear: a review of different theories,” Acta Orthopaedica, vol. 77, no. 2, pp. 177–197, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. J. H. Dumbleton, M. T. Manley, and A. A. Edidin, “A literature review of the association between wear rate and osteolysis in total hip arthroplasty,” Journal of Arthroplasty, vol. 17, no. 5, pp. 649–661, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. T. P. Schmalzried, M. Jasty, and W. H. Harris, “Periprosthetic bone loss in total hip arthroplasty. Polyethylene wear debris and the concept of the effective joint space,” Journal of Bone and Joint Surgery A, vol. 74, no. 6, pp. 849–863, 1992. View at Scopus
  4. K. Hirakawa, T. W. Bauer, B. N. Stulberg, et al., “Comparison and quantitation of wear debris of failed total hip and total knee arthroplasty,” Journal of Biomedical Materials Research, vol. 31, pp. 257–263, 1996.
  5. K. J. Margevicius, T. W. Bauer, J. T. McMahon, S. A. Brown, and K. Merritt, “Isolation and characterization of debris in membranes around total joint prostheses,” Journal of Bone and Joint Surgery A, vol. 76, no. 11, pp. 1664–1675, 1994. View at Scopus
  6. E. M. Schwarz, E. B. Benz, A. P. Lu et al., “Quantitative small-animal surrogate to evaluate drug efficacy in preventing wear debris-induced osteolysis,” Journal of Orthopaedic Research, vol. 18, no. 6, pp. 849–855, 2000. View at Publisher · View at Google Scholar · View at Scopus
  7. P. J. Millett, M. J. Allen, and M. P. G. Bostrom, “Effects of alendronate on particle-induced osteolysis in a rat model,” Journal of Bone and Joint Surgery A, vol. 84, no. 2, pp. 236–249, 2002. View at Scopus
  8. K. D. Merkel, J. M. Erdmann, K. P. McHugh, Y. Abu-Amer, F. P. Ross, and S. L. Teitelbaum, “Tumor necrosis factor-α mediates orthopedic implant osteolysis,” American Journal of Pathology, vol. 154, no. 1, pp. 203–210, 1999. View at Scopus
  9. A. S. Shanbhag, C. T. Hasselman, and H. E. Rubash, “The John Charnley Award. Inhibition of wear debris mediated osteolysis in a canine total hip arthroplasty model,” Clinical Orthopaedics and Related Research, no. 344, pp. 33–43, 1997. View at Scopus
  10. P. H. Wooley, R. Morren, J. Andary et al., “Inflammatory responses to orthopaedic biomaterials in the murine air pouch,” Biomaterials, vol. 23, no. 2, pp. 517–526, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. B. A. Warme, N. J. Epstein, M. C. D. Trindade et al., “Proinflammatory mediator expression in a novel murine model of titanium-particle-induced intramedullary inflammation,” Journal of Biomedical Materials Research B, vol. 71, no. 2, pp. 360–366, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. S.-Y. Yang, B. Wu, L. Mayton et al., “Protective effects of IL-1Ra or vIL-10 gene transfer on a murine model of wear debris-induced osteolysis,” Gene Therapy, vol. 11, no. 5, pp. 483–491, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. T. A. Blaine, R. N. Rosier, J. E. Puzas et al., “Increased levels of tumor necrosis factor-α and interleukin-6 protein and messenger RNA in human peripheral blood monocytes due to titanium particles,” Journal of Bone and Joint Surgery A, vol. 78, no. 8, pp. 1181–1192, 1996. View at Scopus
  14. Y. Nakashima, D.-H. Sun, M. C. D. Trindade et al., “Signaling pathways for tumor necrosis factor-α and interleukin-6 expression in human macrophages exposed to titanium-alloy particulate debris in vitro,” Journal of Bone and Joint Surgery A, vol. 81, no. 5, pp. 603–615, 1999. View at Scopus
  15. J. A. Wimhurst, R. A. Brooks, and N. Rushton, “Inflammatory responses of human primary macrophages to particulate bone cements in vitro,” Journal of Bone and Joint Surgery B, vol. 83, no. 2, pp. 278–282, 2001. View at Scopus
  16. E. Ingham, T. R. Green, M. H. Stone, R. Kowalski, N. Watkins, and J. Fisher, “Production of TNF-α and bone resorbing activity by macrophages in response to different types of bone cement particles,” Biomaterials, vol. 21, no. 10, pp. 1005–1013, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. W. J. Maloney, R. E. James, and R. L. Smith, “Human macrophage response to retrieved titanium alloy particles in vitro,” Clinical Orthopaedics and Related Research, no. 322, pp. 268–278, 1996. View at Scopus
  18. K. J. Saleh, I. Thongtrangan, and E. M. Schwarz, “Osteolysis: medical and surgical approaches,” Clinical Orthopaedics and Related Research, no. 427, pp. 138–147, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. P. E. Purdue, P. Koulouvaris, B. J. Nestor, and T. P. Sculco, “The central role of wear debris in periprosthetic osteolysis,” HSS Journal, vol. 2, no. 2, pp. 102–113, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. T. P. Schmalzried, M. Jasty, and W. H. Harris, “Periprosthetic bone loss in total hip arthroplasty. Polyethylene wear debris and the concept of the effective joint space,” Journal of Bone and Joint Surgery A, vol. 74, no. 6, pp. 849–863, 1992. View at Scopus
  21. T. T. Glant, J. J. Jacobs, G. Molnar, A. S. Shanbhag, M. Valyon, and J. O. Galante, “Bone resorption activity of particulate-stimulated macrophages,” Journal of Bone and Mineral Research, vol. 8, no. 9, pp. 1071–1079, 1993. View at Scopus
  22. M. Goppelt-Struebe and M. Stroebel, “Synergistic induction of monocyte chemoattractant protein-1 (MCP-1) by platelet-derived growth factor and interleukin-1,” FEBS Letters, vol. 374, no. 3, pp. 375–378, 1995. View at Publisher · View at Google Scholar · View at Scopus
  23. S. M. Horowitz and J. B. Gonzales, “Inflammatory response to implant particulates in a macrophage/osteoblast coculture model,” Calcified Tissue International, vol. 59, no. 5, pp. 392–396, 1996. View at Publisher · View at Google Scholar · View at Scopus
  24. N. Ishiguro, T. Kojima, T. Ito et al., “Macrophage activation and migration in interface tissue around loosening total hip arthro­plasty components,” Journal of Biomedical Materials Research, vol. 35, pp. 399–406, 1997.
  25. Y. Kadoya, P. A. Revell, N. Al-Saffar, A. Kobayashi, G. Scott, and M. A. R. Freeman, “Bone formation and bone resorption in failed total joint arthroplasties: histomorphometric analysis with histochemical and immunohistochemical technique,” Journal of Orthopaedic Research, vol. 14, no. 3, pp. 473–482, 1996. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Pizzoferrato, S. Stea, A. Sudanese et al., “Morphometric and microanalytical analyses of alumina wear particles in hip prostheses,” Biomaterials, vol. 14, no. 8, pp. 583–587, 1993. View at Publisher · View at Google Scholar · View at Scopus
  27. D. H. DeHeer, J. A. Engels, A. S. DeVries, et al., “In situ complement activation by polyethylene wear debris,” Journal of Biomedical Materials Research, vol. 54, pp. 12–19, 2001.
  28. S. Santavirta, V. Hoikka, A. Eskola, Y. T. Konttinen, T. Paavilainen, and K. Tallroth, “Aggressive granulomatous lesions in cementless total hip arthroplasty,” Journal of Bone and Joint Surgery B, vol. 72, no. 6, pp. 980–984, 1990. View at Scopus
  29. R. Rezzonico, R. Chicheportiche, V. Imbert, and J.-M. Dayer, “Engagement of CD11b and CD11c β2 integrin by antibodies or soluble CD23 induces IL-1β production on primary human monocytes through mitogen- activated protein kinase-dependent pathways,” Blood, vol. 95, no. 12, pp. 3868–3877, 2000. View at Scopus
  30. R. Rezzonico, V. Imbert, R. Chicheportiche, and J.-M. Dayer, “Ligation of CD11b and CD11c β2 integrins by antibodies or soluble CD23 induces macrophage inflammatory protein 1α (MIP-1α) and MIP-1β production in primary human monocytes through a pathway dependent on nuclear factor-κB,” Blood, vol. 97, no. 10, pp. 2932–2940, 2001. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Palecanda, J. Paulauskis, E. Al-Mutairi et al., “Role of the scavenger receptor MARCO in alveolar macrophage binding of unopsonized environmental particles,” The Journal of Experimental Medicine, vol. 189, no. 9, pp. 1497–1506, 1999. View at Publisher · View at Google Scholar · View at Scopus
  32. D. S. Rakshit, J. T. E. Lim, K. Ly et al., “Involvement of complement receptor 3 (CR3) and scavenger receptor in macrophage responses to wear debris,” Journal of Orthopaedic Research, vol. 24, no. 11, pp. 2036–2044, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. D.-H. Sun, M. C. D. Trindade, Y. Nakashima et al., “Human serum opsonization of orthopedic biomaterial particles: protein-binding and monocyte/macrophage activation in vitro,” Journal of Biomedical Materials Research A, vol. 65, no. 2, pp. 290–298, 2003. View at Scopus
  34. M. Horiki, T. Nakase, A. Myoui et al., “Localization of RANKL in osteolytic tissue around a loosened joint prosthesis,” Journal of Bone and Mineral Metabolism, vol. 22, no. 4, pp. 346–351, 2004. View at Scopus
  35. J. M. W. Quinn, N. J. Horwood, J. Elliott, M. T. Gillespie, and T. J. Martin, “Fibroblastic stromal cells express receptor activator of NF-κB ligand and support osteoclast differentiation,” Journal of Bone and Mineral Research, vol. 15, no. 8, pp. 1459–1466, 2000. View at Scopus
  36. J. Yao, T. T. Glant, M. W. Lark et al., “The potential role of fibroblasts in periprosthetic osteolysis: fibroblast response to titanium particles,” Journal of Bone and Mineral Research, vol. 10, no. 9, pp. 1417–1427, 1995. View at Scopus
  37. M. Manlapaz, W. J. Maloney, and R. L. Smith, “In vitro activation of human fibroblasts by retrieved titanium alloy wear debris,” Journal of Orthopaedic Research, vol. 14, no. 3, pp. 465–472, 1996. View at Publisher · View at Google Scholar · View at Scopus
  38. C. Vermes, R. Chandrasekaran, J. J. Jacobs, J. O. Galante, K. A. Roebuck, and T. T. Glant, “The effects of particulate wear debris, cytokines, and growth factors on the functions of MG-63 osteoblasts,” Journal of Bone and Joint Surgery A, vol. 83, no. 2, pp. 201–211, 2001. View at Scopus
  39. K. Lochner, A. Fritsche, A. Jonitz et al., “The potential role of human osteoblasts for periprosthetic osteolysis following exposure to wear particles,” International Journal of Molecular Medicine, vol. 28, no. 6, pp. 1055–1063, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Sabokbar, O. Kudo, and N. A. Athanasou, “Two distinct cellular mechanisms of osteoclast formation and bone resorption in periprosthetic osteolysis,” Journal of Orthopaedic Research, vol. 21, no. 1, pp. 73–80, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. C.-T. Wang, Y.-T. Lin, B.-L. Chiang, S.-S. Lee, and S.-M. Hou, “Over-expression of receptor activator of nuclear factor-κB ligand (RANKL), inflammatory cytokines, and chemokines in periprosthetic osteolysis of loosened total hip arthroplasty,” Biomaterials, vol. 31, no. 1, pp. 77–82, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. B. Möller and P. M. Villiger, “Inhibition of IL-1, IL-6, and TNF-α in immune-mediated inflammatory diseases,” Springer Seminars in Immunopathology, vol. 27, no. 4, pp. 391–408, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. R. Horai, S. Saijo, H. Tanioka et al., “Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin I receptor antagonist-deficient mice,” The Journal of Experimental Medicine, vol. 191, no. 2, pp. 313–320, 2000. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Caicedo, J. J. Jacobs, and N. J. Hallab, “Inflammatory bone loss in joint replacements: the mechanisms,” Journal Musculoskeletal Medicine, vol. 27, pp. 209–216, 2010.
  45. U. H. Lerner and A. Ohlin, “Tumor necrosis factors α and β can stimulate bone resorption in cultured mouse calvariae by a prostaglandin-independent mechanism,” Journal of Bone and Mineral Research, vol. 8, no. 2, pp. 147–155, 1993. View at Scopus
  46. S. M. Horowitz and M. A. Purdon, “Mediator interactions in macrophage/particulate bone resorption,” Journal of Biomedical Materials Research, vol. 29, no. 4, pp. 477–484, 1995. View at Publisher · View at Google Scholar · View at Scopus
  47. J. Chiba, H. E. Rubash, K. J. Kim, and Y. Iwaki, “The characterization of cytokines in the interface tissue obtained from failed cementless total hip arthroplasty with and without femoral osteolysis,” Clinical Orthopaedics and Related Research, no. 300, pp. 304–312, 1994. View at Scopus
  48. H. Takei, D. Pioletti, S. Y. Kwon, and P. Sung, “Combined effect of titanium particles and TNF-a on the production of IL-6 by osteoblast-like cells,” Journal of Biomedical Materials Research, vol. 52, pp. 382–387, 2000.
  49. M. Gowen, D. D. Wood, E. J. Ihrie, M. K. McGuire, and R. G. Russell, “An interleukin 1 like factor stimulates bone resorption in vitro,” Nature, vol. 306, no. 5941, pp. 378–380, 1983. View at Scopus
  50. T. Akatsu, N. Takahashi, N. Udagawa et al., “Role of prostaglandins in interleukin-1-induced bone resorption in mice in vitro,” Journal of Bone and Mineral Research, vol. 6, no. 2, pp. 183–190, 1991. View at Scopus
  51. S. B. Goodman, R. C. Chin, S. S. Chiou, D. J. Schurman, S. T. Woolson, and M. P. Masada, “A clinical-pathologic-biochemical study of the membrane surrounding loosened and nonloosened total hip arthroplasties,” Clinical Orthopaedics and Related Research, no. 244, pp. 182–187, 1989. View at Scopus
  52. W. A. Jiranek, M. Machado, M. Jasty et al., “Production of cytokines around loosened cemented acetabular components: analysis with immunohistochemical techniques and in situ hybridization,” Journal of Bone and Joint Surgery A, vol. 75, no. 6, pp. 863–879, 1993. View at Scopus
  53. K. Kusano, C. Miyaura, M. Inada et al., “Regulation of matrix metalloproteinases (MMP-2,-3,-9, and -13) by interleukin-1 and interleukin-6 in mouse calvaria: association of MMP induction with bone resorption,” Endocrinology, vol. 139, no. 3, pp. 1338–1345, 1998. View at Publisher · View at Google Scholar · View at Scopus
  54. Y. Ishimi, C. Miyaura, C. H. Jin et al., “IL-6 is produced by osteoblasts and induces bone resorption,” Journal of Immunology, vol. 145, no. 10, pp. 3297–3303, 1990. View at Scopus
  55. N. Kurihara, D. Bertolini, T. Suda, Y. Akiyama, and G. D. Roodman, “IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release,” Journal of Immunology, vol. 144, no. 11, pp. 4226–4230, 1990. View at Scopus
  56. S. R. Goldring, M. Jasty, M. S. Roelke, C. M. Rourke, F. R. Bringhurst, and W. H. Harris, “Formation of a synovial-like membrane at the bone-cement interface. Its role in bone resorption and implant loosening after total hip replacement,” Arthritis and Rheumatism, vol. 29, no. 7, pp. 836–842, 1986. View at Scopus
  57. A. M. Appel, W. G. Sowder, S. W. Siverhus, C. N. Hopson, and J. H. Herman, “Prosthesis-associated pseudomembrane-induced bone resorption,” British Journal of Rheumatology, vol. 29, no. 1, pp. 32–36, 1990. View at Scopus
  58. M. Takagi, Y. T. Konttinen, S. Santavirta et al., “Extracellular matrix metalloproteinases around loose total hip prostheses,” Acta Orthopaedica Scandinavica, vol. 65, no. 3, pp. 281–286, 1994. View at Scopus
  59. E. A. Fritz, T. T. Glant, C. Vermes, J. J. Jacobs, and K. A. Roebuck, “Chemokine gene activation in human bone marrow-derived osteoblasts following exposure to particulate wear debris,” Journal of Biomedical Materials Research A, vol. 77, no. 1, pp. 192–201, 2006. View at Publisher · View at Google Scholar · View at Scopus
  60. Z. Huang, T. Ma, P.-G. Ren, R. L. Smith, and S. B. Goodman, “Effects of orthopedic polymer particles on chemotaxis of macrophages and mesenchymal stem cells,” Journal of Biomedical Materials Research A, vol. 94, no. 4, pp. 1264–1269, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. S. B. Goodman and T. Ma, “Cellular chemotaxis induced by wear particles from joint replacements,” Biomaterials, vol. 31, no. 19, pp. 5045–5050, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. M. Hukkanen, S. A. Corbett, J. Batten et al., “Aseptic loosening of total hip replacement. Macrophage expression of inducible nitric oxide synthase and cyclo-oxygenase-2, together with peroxynitrite formation, as a possible mechanism for early prosthesis failure,” Journal of Bone and Joint Surgery B, vol. 79, no. 3, pp. 467–474, 1997. View at Publisher · View at Google Scholar · View at Scopus
  63. S. G. Harris, J. Padilla, L. Koumas, D. Ray, and R. P. Phipps, “Prostaglandins as modulators of immunity,” Trends in Immunology, vol. 23, no. 3, pp. 144–150, 2002. View at Publisher · View at Google Scholar · View at Scopus
  64. K. T. Steeve, P. Marc, T. Sandrine, H. Dominique, and F. Yannick, “IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology,” Cytokine and Growth Factor Reviews, vol. 15, no. 1, pp. 49–60, 2004. View at Publisher · View at Google Scholar · View at Scopus
  65. H. Nagase, R. Visse, and G. Murphy, “Structure and function of matrix metalloproteinases and TIMPs,” Cardiovascular Research, vol. 69, no. 3, pp. 562–573, 2006. View at Publisher · View at Google Scholar · View at Scopus
  66. K. J. Leco, P. Waterhouse, O. H. Sanchez, et al., “Spontaneous air space enlargement in the lungs of mice lacking tissue inhibitor of metalloproteinases-3 (TIMP-3),” The Journal of Clinical Investigation, vol. 108, pp. 817–829, 2001.
  67. J. E. Fata, K. J. Leco, E. B. Voura et al., “Accelerated apoptosis in the Timp-3-deficient mammary gland,” The Journal of Clinical Investigation, vol. 108, no. 6, pp. 831–841, 2001. View at Publisher · View at Google Scholar · View at Scopus
  68. J. L. English, Z. Kassiri, I. Koskivirta et al., “Individual Timp deficiencies differentially impact pro-MMP-2 activation,” The Journal of Biological Chemistry, vol. 281, no. 15, pp. 10337–10346, 2006. View at Publisher · View at Google Scholar · View at Scopus
  69. J. M. Ray and W. G. Stetler-Stevenson, “The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis,” European Respiratory Journal, vol. 7, no. 11, pp. 2062–2072, 1994. View at Scopus
  70. I. Takei, M. Takagi, S. Santavirta et al., “Messenger ribonucleic acid expression of 16 matrix metalloproteinases in bone-implant interface tissues of loose artificial hip joints,” Journal of Biomedical Materials Research, vol. 52, pp. 613–620, 2000.
  71. K. Sasaki, M. Takagi, J. Mandelin et al., “Quantitative analysis of mRNA expression of TIMPs in the periprosthetic interface tissue of loose hips by real-time PCR system,” Journal of Biomedical Materials Research, vol. 58, no. 6, pp. 605–612, 2001. View at Publisher · View at Google Scholar · View at Scopus
  72. T.-F. Li, S. Santavirta, I. Virtanen, M. Könönen, M. Takagi, and Y. T. Konttinen, “Increased expression of EMMPRIN in the tissue around loosened hip prostheses,” Acta Orthopaedica Scandinavica, vol. 70, no. 5, pp. 446–451, 1999. View at Scopus
  73. B. Nawrocki, M. Polette, H. Burlet, P. Birembaut, and J.-J. Adnet, “Expression of gelatinase A and its activator MT1-MMP in the inflammatory periprosthetic response to polyethylene,” Journal of Bone and Mineral Research, vol. 14, no. 2, pp. 288–294, 1999. View at Publisher · View at Google Scholar · View at Scopus
  74. R. M. Hembry, M. R. Bagga, J. J. Reynolds, and D. L. Hamblen, “Stromelysin, gelatinase A and TIMP-1 in prosthetic interface tissue: a role for macrophages in tissue remodelling,” Histopathology, vol. 27, no. 2, pp. 149–159, 1995. View at Scopus
  75. M. Takagi, “Neutral proteinases and their inhibitors in the loosening of total hip prostheses,” Acta orthopaedica Scandinavica. Supplementum, vol. 271, pp. 3–29, 1996. View at Scopus
  76. Y. Yokohama, T. Matsumoto, M. Hirakawa et al., “Production of matrix metalloproteinases at the bone-implant interface in loose total hip replacements,” Laboratory Investigation, vol. 73, no. 6, pp. 899–911, 1995. View at Scopus
  77. M. Takagi, Y. T. Konttinen, O. Lindy et al., “Gelatinase/Type IV collagenases in the loosening of total hip replacement endoprostheses,” Clinical Orthopaedics and Related Research, no. 306, pp. 136–144, 1994. View at Scopus
  78. M. Takagi, Y. T. Konttinen, P. Kemppinen et al., “Tissue inhibitor of metalloproteinase 1, collagenolytic and gelatinolytic activity in loose hip endoprostheses,” Journal of Rheumatology, vol. 22, no. 12, pp. 2285–2290, 1995. View at Scopus
  79. S. Santavirta, M. Takagi, Y. T. Konttinen, T. Sorsa, and A. Suda, “Inhibitory effect of cephalothin on matrix metalloproteinase activity around loose hip prostheses,” Antimicrobial Agents and Chemotherapy, vol. 40, no. 1, pp. 244–246, 1996. View at Scopus
  80. N. Ishiguro, T. Ito, K. Kurokouchi et al., “mRNA expression of matrix metalloproteinases and tissue inhibitors of metalloproteinase in interface tissue around implants in loosening total hip arthroplasty,” Journal of Biomedical Materials Research, vol. 32, pp. 611–617, 1996.
  81. A. Y. Strongin, I. Collier, G. Bannikov, B. L. Marmer, G. A. Grant, and G. I. Goldberg, “Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease,” The Journal of Biological Chemistry, vol. 270, no. 10, pp. 5331–5338, 1995. View at Publisher · View at Google Scholar · View at Scopus
  82. S. A. Syggelos, S. C. Eleftheriou, E. Giannopoulou, E. Panagiotopoulos, and A. J. Aletras, “Gelatinolytic and collagenolytic activity in periprosthetic tissues from loose hip endoprostheses,” Journal of Rheumatology, vol. 28, no. 6, pp. 1319–1329, 2001. View at Scopus
  83. G. I. Goldberg, S. M. Wilhelm, A. Kronberger, E. A. Bauer, G. A. Grant, and A. Z. Eisen, “Human fibroblast collagenase,” The Journal of Biological Chemistry, vol. 261, pp. 6600–6605, 1986.
  84. K. A. Hasty, J. J. Jeffrey, M. S. Hibbs, and H. G. Welgus, “The collagen substrate specificity of human neutrophil collagenase,” The Journal of Biological Chemistry, vol. 262, no. 21, pp. 10048–10052, 1987. View at Scopus
  85. T. J. Chambers, J. A. Darby, and K. Fuller, “Mammalian collagenase predisposes bone surfaces to osteoclastic resorption,” Cell and Tissue Research, vol. 241, no. 3, pp. 671–675, 1985. View at Scopus
  86. L. Nordsletten, L. Buø, M. Takagi et al., “The plasminogen activation system is upregulated in loosening of total hip prostheses,” Acta Orthopaedica Scandinavica, vol. 67, no. 2, pp. 143–148, 1996. View at Scopus
  87. I. Kazes, F. Delarue, J. Hagège et al., “Soluble latent membrane-type 1 matrix metalloprotease secreted by human mesangial cells is activated by urokinase,” Kidney International, vol. 54, no. 6, pp. 1976–1984, 1998. View at Publisher · View at Google Scholar · View at Scopus
  88. P. Carmeliet, L. Moons, R. Lijnen et al., “Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation,” Nature Genetics, vol. 17, no. 4, pp. 439–444, 1997. View at Scopus
  89. P. Diehl, B. Hantke, M. Hennig et al., “Protein expression of MMP-13, uPA, and PAI-1 in pseudocapsular and interface tissue around implants of loose artificial hip joints and in osteoarthritis,” International Journal of Molecular Medicine, vol. 13, no. 5, pp. 711–715, 2004. View at Scopus
  90. Y. Nakashima, D.-H. Sun, W. J. Maloney, S. B. Goodman, D. J. Schurman, and R. L. Smith, “Induction of matrix metalloproteinase expression in human macrophages by orthopaedic particulate debris in vitro,” Journal of Bone and Joint Surgery B, vol. 80, no. 4, pp. 694–700, 1998. View at Publisher · View at Google Scholar · View at Scopus
  91. P. Laquerriere, A. Grandjean-Laquerriere, S. Addadi-Rebbah et al., “MMP-2, MMP-9 and their inhibitors TIMP-2 and TIMP-1 production by human monocytes in vitro in the presence of different forms of hydroxyapatite particles,” Biomaterials, vol. 25, no. 13, pp. 2515–2524, 2004. View at Publisher · View at Google Scholar · View at Scopus
  92. T. Ikeda, M. Kasai, M. Utsuyama, and K. Hirokawa, “Determination of three isoforms of the receptor activator of nuclear factor-κB ligand and their differential expression in bone and thymus,” Endocrinology, vol. 142, no. 4, pp. 1419–1426, 2001. View at Publisher · View at Google Scholar · View at Scopus
  93. W. J. Boyle, W. S. Simonet, and D. L. Lacey, “Osteoclast differentiation and activation,” Nature, vol. 423, no. 6937, pp. 337–342, 2003. View at Publisher · View at Google Scholar · View at Scopus
  94. E. M. Schwarz, A. P. Lu, J. J. Goater et al., “Tumor necrosis factor-α/nuclear transcription factor-κB signaling in periprosthetic osteolysis,” Journal of Orthopaedic Research, vol. 18, no. 3, pp. 472–480, 2000. View at Scopus
  95. J. C. Clohisy, T. Hirayama, E. Frazier, S.-K. Han, and Y. Abu-Amer, “NF-kB signaling blockade abolishes implant particle-induced osteoclastogenesis,” Journal of Orthopaedic Research, vol. 22, no. 1, pp. 13–20, 2004. View at Publisher · View at Google Scholar · View at Scopus
  96. W. Ren, X. H. Li, B. D. Chen, and P. H. Wooley, “Erythromycin inhibits wear debris-induced osteoclastogenesis by modulation of murine macrophage NF-κB activity,” Journal of Orthopaedic Research, vol. 22, no. 1, pp. 21–29, 2004. View at Publisher · View at Google Scholar · View at Scopus
  97. F. Lamoureux, G. Moriceau, G. Picarda, J. Rousseau, V. Trichet, and F. Rédini, “Regulation of osteoprotegerin pro- or anti-tumoral activity by bone tumor microenvironment,” Biochimica et Biophysica Acta, vol. 1805, no. 1, pp. 17–24, 2010. View at Publisher · View at Google Scholar · View at Scopus
  98. M. Ulrich-Vinther, E. E. Carmody, J. J. Goater, K. Soøballe, R. J. O'Keefe, and E. M. Schwarz, “Recombinant adeno-associated virus-mediated osteoprotegerin gene therapy inhibits wear debris-induced osteolysis,” Journal of Bone and Joint Surgery A, vol. 84, no. 8, pp. 1405–1412, 2002. View at Scopus
  99. J. Jeffrey Goater, R. J. O'Keefe, R. N. Rosier, J. Edward Puzas, and E. M. Schwarz, “Efficacy of ex vivo OPG gene therapy in preventing wear debris induced osteolysis,” Journal of Orthopaedic Research, vol. 20, no. 2, pp. 169–173, 2002. View at Publisher · View at Google Scholar · View at Scopus
  100. L. M. Childs, E. P. Paschalis, L. Xing et al., “In vivo RANK signaling blockade using the receptor activator of NF-κB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis,” Journal of Bone and Mineral Research, vol. 17, no. 2, pp. 192–199, 2002. View at Scopus
  101. T. Masui, S. Sakano, Y. Hasegawa, H. Warashina, and N. Ishiguro, “Expression of inflammatory cytokines, RANKL and OPG induced by titanium, cobalt-chromium and polyethylene particles,” Biomaterials, vol. 26, no. 14, pp. 1695–1702, 2005. View at Publisher · View at Google Scholar · View at Scopus
  102. J. Mandelin, T.-F. Li, M. Liljeström et al., “Imbalance of RANKL/RANK/OPG system in interface tissue in loosening of total hip replacement,” Journal of Bone and Joint Surgery B, vol. 85, no. 8, pp. 1196–1201, 2003. View at Publisher · View at Google Scholar · View at Scopus
  103. T. Gehrke, C. Sers, L. Morawietz et al., “Receptor activator of nuclear factor κB ligand is expressed in resident and inflammatory cells in aseptic and septic prosthesis loosening,” Scandinavian Journal of Rheumatology, vol. 32, no. 5, pp. 287–294, 2003. View at Publisher · View at Google Scholar · View at Scopus
  104. D. R. Haynes, T. N. Crotti, A. E. Potter et al., “The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis,” Journal of Bone and Joint Surgery B, vol. 83, no. 6, pp. 902–911, 2001. View at Scopus
  105. M. Horiki, T. Nakase, A. Myoui et al., “Localization of RANKL in osteolytic tissue around a loosened joint prosthesis,” Journal of Bone and Mineral Metabolism, vol. 22, no. 4, pp. 346–351, 2004. View at Scopus
  106. J. Mandelin, T.-F. Li, M. Hukkanen et al., “Interface tissue fibroblasts from loose total hip replacement prosthesis produce receptor activator of nuclear factor-κB ligand, osteoprotegerin, and cathepsin K,” Journal of Rheumatology, vol. 32, no. 4, pp. 713–720, 2005. View at Scopus
  107. V. T. Labropoulou, A. D. Theocharis, A. Symeonidis, S. S. Skandalis, N. K. Karamanos, and H. P. Kalofonos, “Pathophysiology and pharmacological targeting of tumor-induced bone disease: current status and emerging therapeutic interventions,” Current Medicinal Chemistry, vol. 18, no. 11, pp. 1584–1598, 2011. View at Publisher · View at Google Scholar · View at Scopus
  108. O. Ishibashi, S. Niwa, K. Kadoyama, and T. Inui, “MMP-9 antisense oligodeoxynucleotide exerts an inhibitory effect on osteoclastic bone resorption by suppressing cell migration,” Life Sciences, vol. 79, no. 17, pp. 1657–1660, 2006. View at Publisher · View at Google Scholar · View at Scopus
  109. W. C. M. Duivenvoorden, H. W. Hirte, and G. Singh, “Use of tetracycline as an inhibitor of matrix metalloproteinase activity secreted by human bone-metastasizing cancer cells,” Invasion and Metastasis, vol. 17, no. 6, pp. 312–322, 1997. View at Scopus
  110. G. C. N. Franco, M. Kajiya, T. Nakanishi et al., “Inhibition of matrix metalloproteinase-9 activity by doxycycline ameliorates RANK ligand-induced osteoclast differentiation in vitro and in vivo,” Experimental Cell Research, vol. 317, no. 10, pp. 1454–1464, 2011. View at Publisher · View at Google Scholar · View at Scopus
  111. L. Blavier and J. M. Delaissé, “Matrix metalloproteinases are obligatory for the migration of preosteoclasts to the developing marrow cavity of primitive long bones,” Journal of Cell Science, vol. 108, no. 12, pp. 3649–3659, 1995. View at Scopus
  112. M. T. Engsig, Q.-J. Chen, T. H. Vu et al., “Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for osteoclast recruitment into developing long bones,” Journal of Cell Biology, vol. 151, no. 4, pp. 879–889, 2000. View at Publisher · View at Google Scholar · View at Scopus
  113. C. C. Lynch, A. Hikosaka, H. B. Acuff et al., “MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL,” Cancer Cell, vol. 7, no. 5, pp. 485–496, 2005. View at Publisher · View at Google Scholar · View at Scopus
  114. T. J. Wilson, K. C. Nannuru, M. Futakuchi, A. Sadanandam, and R. K. Singh, “Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-κB ligand,” Cancer Research, vol. 68, no. 14, pp. 5803–5811, 2008. View at Publisher · View at Google Scholar · View at Scopus
  115. S. Thiolloy, J. Halpern, G. E. Holt et al., “Osteoclast-derived matrix metalloproteinase-7, but not matrix metalloproteinase-9, contributes to tumor-induced osteolysis,” Cancer Research, vol. 69, no. 16, pp. 6747–6755, 2009. View at Publisher · View at Google Scholar · View at Scopus
  116. T. Standal, C. Seidel, Ø. Hjertner et al., “Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells,” Blood, vol. 100, no. 8, pp. 3002–3007, 2002. View at Publisher · View at Google Scholar · View at Scopus
  117. W. S. Simonet, D. L. Lacey, C. R. Dunstan et al., “Osteoprotegerin: a novel secreted protein involved in the regulation of bone density,” Cell, vol. 89, no. 2, pp. 309–319, 1997. View at Scopus
  118. T. Manon-Jensen, Y. Itoh, and J. R. Couchman, “Proteoglycans in health and disease: the multiple roles of syndecan shedding,” FEBS Journal, vol. 277, no. 19, pp. 3876–3889, 2010. View at Publisher · View at Google Scholar · View at Scopus
  119. Q. Li, P. W. Park, C. L. Wilson, and W. C. Parks, “Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury,” Cell, vol. 111, no. 5, pp. 635–646, 2002. View at Publisher · View at Google Scholar · View at Scopus
  120. S. Brule, N. Charnaux, A. Sutton et al., “The shedding of syndecan-4 and syndecan-1 from HeLa cells and human primary macrophages is accelerated by SDF-1/CXCL12 and mediated by the matrix metalloproteinase-9,” Glycobiology, vol. 16, no. 6, pp. 488–501, 2006. View at Publisher · View at Google Scholar · View at Scopus
  121. C. Y. Fears, C. L. Gladson, and A. Woods, “Syndecan-2 is expressed in the microvasculature of gliomas and regulates angiogenic processes in microvascular endothelial cells,” The Journal of Biological Chemistry, vol. 281, no. 21, pp. 14533–14536, 2006. View at Publisher · View at Google Scholar · View at Scopus
  122. K. Endo, T. Takino, H. Miyamori et al., “Cleavage of syndecan-1 by membrane type matrix metalloproteinase-1 stimulates cell migration,” The Journal of Biological Chemistry, vol. 278, no. 42, pp. 40764–40770, 2003. View at Publisher · View at Google Scholar · View at Scopus
  123. C. Vermes, K. A. Roebuck, R. Chandrasekaran, J. G. Dobai, J. J. Jacobs, and T. T. Glant, “Particulate wear debris activates protein tyrosine kinases and nuclear factor κB, which down-regulates type I collagen synthesis in human osteoblasts,” Journal of Bone and Mineral Research, vol. 15, no. 9, pp. 1756–1765, 2000. View at Scopus
  124. L. Luo, A. Petit, J. Antoniou et al., “Effect of cobalt and chromium ions on MMP-1, TIMP-1, and TNF-α gene expression in human U937 macrophages: a role for tyrosine kinases,” Biomaterials, vol. 26, no. 28, pp. 5587–5593, 2005. View at Publisher · View at Google Scholar · View at Scopus
  125. G.-R. Yan, C.-L. Xiao, G.-W. He et al., “Global phosphoproteomic effects of natural tyrosine kinase inhibitor, genistein, on signaling pathways,” Proteomics, vol. 10, no. 5, pp. 976–986, 2010. View at Publisher · View at Google Scholar · View at Scopus
  126. X. N. Stahtea, O. C. Kousidou, A. E. Roussidis, G. N. Tzanakakis, and N. K. Karamanos, “Small tyrosine kinase inhibitors as key molecules in the expression of metalloproteinases by solid tumors,” Connective Tissue Research, vol. 49, no. 3-4, pp. 211–214, 2008. View at Publisher · View at Google Scholar · View at Scopus
  127. M. H. Ravindranath, S. Muthugounder, N. Presser, and S. Viswanathan, “Anticancer therapeutic potential of soy isoflavone, genistein,” Advances in Experimental Medicine and Biology, vol. 546, pp. 121–165, 2004. View at Scopus
  128. D. S. Goodsell, “The molecular perspective: VEGF and angiogenesis,” Oncologist, vol. 7, no. 6, pp. 569–570, 2002. View at Publisher · View at Google Scholar · View at Scopus
  129. L. E. Harry and E. M. Paleolog, “From the cradle to the clinic: VEGF in developmental, physiological, and pathological angiogenesis,” Birth Defects Research C, vol. 69, no. 4, pp. 363–374, 2003. View at Publisher · View at Google Scholar · View at Scopus
  130. J. Waltenberger, L. Claesson-Welsh, A. Siegbahn, M. Shibuya, and C.-H. Heldin, “Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor,” The Journal of Biological Chemistry, vol. 269, no. 43, pp. 26988–26995, 1994. View at Scopus
  131. R. Kunstfeld, S. Hirakawa, Y.-K. Hong et al., “Induction of cutaneous delayed-type hypersensitivity reactions in VEGF-A transgenic mice results in chronic skin inflammation associated with persistent lymphatic hyperplasia,” Blood, vol. 104, no. 4, pp. 1048–1057, 2004. View at Publisher · View at Google Scholar · View at Scopus
  132. M. Nakagawa, T. Kaneda, T. Arakawa et al., “Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts,” FEBS Letters, vol. 473, no. 2, pp. 161–164, 2000. View at Publisher · View at Google Scholar · View at Scopus
  133. K. Henriksen, M. Karsdal, J.-M. Delaissé, and M. T. Engsig, “RANKL and vascular endothelial growth factor (VEGF) induce osteoclast chemotaxis through an ERK1/2-dependent mechanism,” The Journal of Biological Chemistry, vol. 278, no. 49, pp. 48745–48753, 2003. View at Publisher · View at Google Scholar · View at Scopus
  134. N. Al-Saffar, J. T. L. Mah, Y. Kadoya, and P. A. Revell, “Neovascularisation and the induction of cell adhesion molecules in response to degradation products from orthopaedic implants,” Annals of the Rheumatic Diseases, vol. 54, no. 3, pp. 201–208, 1995. View at Scopus
  135. J. Y. Wang, B. H. Wicklund, R. B. Gustilo, and D. T. Tsukayama, “Titanium, chromium and cobalt ions modulate the release of bone-associated cytokines by human monocytes/macrophages in vitro,” Biomaterials, vol. 17, no. 23, pp. 2233–2240, 1996. View at Publisher · View at Google Scholar · View at Scopus
  136. Y. Niki, H. Matsumoto, Y. Suda et al., “Metal ions induce bone-resorbing cytokine production through the redox pathway in synoviocytes and bone marrow macrophages,” Biomaterials, vol. 24, no. 8, pp. 1447–1457, 2003. View at Publisher · View at Google Scholar · View at Scopus
  137. O. Langholz, D. Röckel, C. Mauch et al., “Collagen and collagenase gene expression in three-dimensional collagen lattices are differentially regulated by α1β1 and α2β1 integrins,” Journal of Cell Biology, vol. 131, no. 6, pp. 1903–1915, 1995. View at Publisher · View at Google Scholar · View at Scopus
  138. L. Ravanti, J. Heino, C. López-Otín, and V. M. Kaharin, “Induction of collagenase-3 (MMP-13) expression in human skin fibroblasts by three-dimensional collagen is mediated by p38 mitogen-activated protein kinase,” The Journal of Biological Chemistry, vol. 274, pp. 2446–2455, 1999.
  139. Y. Tamaki, Y. Takakubo, K. Goto et al., “Increased expression of toll-like receptors in aseptic loose periprosthetic tissues and septic synovial membranes around total hip implants,” Journal of Rheumatology, vol. 36, no. 3, pp. 598–608, 2009. View at Publisher · View at Google Scholar · View at Scopus
  140. J. A. Gebbia, J. L. Coleman, and J. L. Benach, “Selective induction of matrix metalloproteinases by Borrelia burgdorferi via Toll-like receptor 2 in monocytes,” Journal of Infectious Diseases, vol. 189, no. 1, pp. 113–119, 2004. View at Publisher · View at Google Scholar · View at Scopus
  141. R. A. Lisboa, M. V. Andrade, and J. R. Cunha-Melo, “Toll-like receptor activation and mechanical force stimulation promote the secretion of matrix metalloproteinases 1, 3 and 10 of human periodontal fibroblasts via p38, JNK and NF-kB,” Archives of Oral Biology, vol. 58, no. 6, pp. 731–739, 2013.
  142. M. H. A. Malik, F. Jury, A. Bayat, W. E. R. Ollier, and P. R. Kay, “Genetic susceptibility to total hip arthroplasty failure: a preliminary study on the influence of matrix metalloproteinase 1, interleukin 6 polymorphisms and vitamin D receptor,” Annals of the Rheumatic Diseases, vol. 66, no. 8, pp. 1116–1120, 2007. View at Publisher · View at Google Scholar · View at Scopus
  143. S. Ye, “Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases,” Matrix Biology, vol. 19, no. 7, pp. 623–629, 2000. View at Publisher · View at Google Scholar · View at Scopus
  144. U. Benbow, J. L. Rutter, C. H. Lowrey, and C. E. Brinckerhoff, “Transcriptional repression of the human collagenase-1 (MMP-1) gene in MDA231 breast cancer cells by all-trans-retinoic acid requires distal regions of the promoter,” British Journal of Cancer, vol. 79, no. 2, pp. 221–228, 1999. View at Scopus
  145. S. R. Bramhall, A. Rosemurgy, P. D. Brown, C. Bowry, and J. A. C. Buckles, “Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial,” Journal of Clinical Oncology, vol. 19, no. 15, pp. 3447–3455, 2001. View at Scopus
  146. P. C. Ortiz-Lazareno, G. Hernandez-Flores, J. R. Dominguez-Rodriguez et al., “MG132 proteasome inhibitor modulates proinflammatory cytokines production and expression of their receptors in U937 cells: involvement of nuclear factor-κB and activator protein-1,” Immunology, vol. 124, no. 4, pp. 534–541, 2008. View at Publisher · View at Google Scholar · View at Scopus
  147. X. Mao, X. Pan, T. Cheng, and X. Zhang, “Inhibition of titanium particle-induced inflammation by the proteasome inhibitor bortezomib in murine macrophage-like RAW 264.7 cells,” Inflammation, vol. 35, no. 4, pp. 1411–1418, 2012. View at Publisher · View at Google Scholar · View at Scopus
  148. T. Krakauer, “Molecular therapeutic targets in inflammation: cyclooxygenase and NF-κB,” Current Drug Targets, vol. 3, no. 3, pp. 317–324, 2004. View at Publisher · View at Google Scholar · View at Scopus
  149. L. Goffin, Q. Seguin-Estévez, M. Alvarez, W. Reith, and C. Chizzolini, “Transcriptional regulation of matrix metalloproteinase-1 and collagen 1A2 explains the anti-fibrotic effect exerted by proteasome inhibition in human dermal fibroblasts,” Arthritis Research and Therapy, vol. 12, no. 2, article 73, 2010. View at Publisher · View at Google Scholar · View at Scopus
  150. T. Smallie, G. Ricchetti, N. J. Horwood, M. Feldmann, A. R. Clark, and L. M. Williams, “IL-10 inhibits transcription elongation of the human TNF gene in primary macrophages,” The Journal of Experimental Medicine, vol. 207, no. 10, pp. 2081–2088, 2010. View at Publisher · View at Google Scholar · View at Scopus
  151. A. B. Lentsch, T. P. Shanley, V. Sarma, and P. A. Ward, “In vivo suppression of NF-κB and preservation of IκBα by interleukin- 10 and interleukin-13,” The Journal of Clinical Investigation, vol. 100, no. 10, pp. 2443–2448, 1997. View at Scopus
  152. N. Giuliani, F. Morandi, S. Tagliaferri et al., “The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients,” Blood, vol. 110, no. 1, pp. 334–338, 2007. View at Publisher · View at Google Scholar · View at Scopus
  153. E. Terpos, D. J. Heath, A. Rahemtulla et al., “Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-κB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma,” British Journal of Haematology, vol. 135, no. 5, pp. 688–692, 2006. View at Publisher · View at Google Scholar · View at Scopus
  154. I. von Metzler, H. Krebbel, M. Hecht et al., “Bortezomib inhibits human osteoclastogenesis,” Leukemia, vol. 21, no. 9, pp. 2025–2034, 2007. View at Publisher · View at Google Scholar · View at Scopus
  155. V. J. Palombella, O. J. Rando, A. L. Goldberg, and T. Maniatis, “The ubiquitin-proteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB,” Cell, vol. 78, no. 5, pp. 773–785, 1994. View at Publisher · View at Google Scholar · View at Scopus
  156. E. Reinstein and A. Ciechanover, “Narrative review: potein degradation and human diseases: the ubiquitin connection,” Annals of Internal Medicine, vol. 145, no. 9, pp. 676–684, 2006. View at Scopus
  157. S. S. Skandalis, A. J. Aletras, C. Gialeli et al., “Targeting the tumor proteasome as a mechanism to control the synthesis and bioactivity of matrix macromolecules,” Current Molecular Medicine, vol. 12, pp. 1068–1082, 2012.
  158. M. L. Wang, P. V. Hauschka, R. S. Tuan, and M. J. Steinbeck, “Exposure to particles stimulates superoxide production by human THP-1 macrophages and A vian HD-11EM osteoclasts activated by tumor necrosis factor-α and PMA,” Journal of Arthroplasty, vol. 17, no. 3, pp. 335–346, 2002. View at Publisher · View at Google Scholar · View at Scopus
  159. H.-M. Wu, K.-H. Chi, and W.-W. Lin, “Proteasome inhibitors stimulate activator protein-1 pathway via reactive oxygen species production,” FEBS Letters, vol. 526, no. 1–3, pp. 101–105, 2002. View at Publisher · View at Google Scholar · View at Scopus
  160. B. Catalgol, I. Ziaja, N. Breusing et al., “The proteasome is an integral part of solar ultraviolet a radiation-induced gene expression,” The Journal of Biological Chemistry, vol. 284, no. 44, pp. 30076–30086, 2009. View at Publisher · View at Google Scholar · View at Scopus
  161. S. Fineschi, W. Reith, P. A. Guerne, J.-M. Dayer, and C. Chizzolini, “Proteasome blockade exerts an antifibrotic activity by coordinately down-regulating type I collagen and tissue inhibitor of metalloproteinase-1 and up-regulating metalloproteinase-1 production in human dermal fibroblasts,” FASEB Journal, vol. 20, no. 3, pp. 562–564, 2006. View at Publisher · View at Google Scholar · View at Scopus
  162. H.-J. Kim, B. Barajas, M. Wang, and A. E. Nel, “Nrf2 activation by sulforaphane restores the age-related decrease of TH1 immunity: role of dendritic cells,” Journal of Allergy and Clinical Immunology, vol. 121, no. 5, pp. 1255–1261, 2008. View at Publisher · View at Google Scholar · View at Scopus
  163. L. Sepp-Lorenzino, Z. Ma, D. E. Lebwohl, A. Vinitsky, and N. Rosen, “Herbimycin A induces the 20 S proteasome- and ubiquitin-dependent degradation of receptor tyrosine kinases,” The Journal of Biological Chemistry, vol. 270, no. 28, pp. 16580–16587, 1995. View at Publisher · View at Google Scholar · View at Scopus
  164. D. C. Markel, R. Zhang, T. Shi, M. Hawkins, and W. Ren, “Inhibitory effects of erythromycin on wear debris-induced VEGF/Flt-1 gene production and osteolysis,” Inflammation Research, vol. 58, pp. 413–421, 2009. View at Publisher · View at Google Scholar · View at Scopus
  165. P. J. Millett, M. J. Allen, and M. P. G. Bostrom, “Effects of alendronate on particle-induced osteolysis in a rat model,” Journal of Bone and Joint Surgery A, vol. 84, no. 2, pp. 236–249, 2002. View at Scopus
  166. M. von Knoch, C. Wedemeyer, A. Pingsmann et al., “The decrease of particle-induced osteolysis after a single dose of bisphosphonate,” Biomaterials, vol. 26, no. 14, pp. 1803–1808, 2005. View at Publisher · View at Google Scholar · View at Scopus
  167. P. G. Dedes, C. Gialeli, A. Tsonis et al., “Expression of matrix macromolecules and functional properties of breast cancer cells are modulated by the bisphosphonate zoledronic acid,” Biochimica et Biophysica Acta, vol. 1820, pp. 1926–1939, 2012.
  168. A. Ito, T. Nose, S. Takahashi, and Y. Mori, “Cyclooxygenase inhibitors augment the production of pro-matrix metalloproteinase 9 (progelatinase B) in rabbit articular chondrocytes,” FEBS Letters, vol. 360, no. 1, pp. 75–79, 1995. View at Publisher · View at Google Scholar · View at Scopus
  169. J. A. DiBattista, J. Martel-Pelletier, N. Fujimoto, K. Obata, M. Zafarullah, and J.-P. Pelletier, “Prostaglandins E2 and E1 inhibit cytokine-induced metalloprotease expression in human synovial fibroblasts: mediation by cyclic-AMP signalling pathway,” Laboratory Investigation, vol. 71, no. 2, pp. 270–278, 1994. View at Scopus
  170. S. Takahashi, T. Inoue, M. Higaki, and Y. Mizushima, “Cyclooxygenase inhibitors enhance the production of tissue inhibitor-1 of metalloproteinases (TIMP-1) and pro-matrix metalloproteinase 1 (proMMP-1) in human rheumatoid synovial fibroblasts,” Inflammation Research, vol. 46, no. 8, pp. 320–323, 1997. View at Publisher · View at Google Scholar · View at Scopus
  171. S. K. Lin, C. C. Wang, S. Huang et al., “Induction of dental pulp fibroblast matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 gene expression by interleukin-1alpha and tumor necrosis factor-alpha through a prostaglandin-dependent pathway,” Journal of Endodontics, vol. 27, no. 3, pp. 185–189, 2001. View at Scopus
  172. R. Yamazaki, S. Kawai, Y. Mizushima et al., “A major metabolite of aceclofenac, 4'-hydroxy aceclofenac, suppresses the production of interstitial pro-collagenase/proMMP-1 and pro-stromelysin- 1/proMMP-3 by human rheumatoid synovial cells,” Inflammation Research, vol. 49, no. 3, pp. 133–138, 2000. View at Scopus
  173. H. Akimoto, R. Yamazaki, S. Hashimoto, T. Sato, and A. Ito, “4′-Hydroxy aceclofenac suppresses the interleukin-1-induced production of promatrix metalloproteinases and release of sulfated-glycosaminoglycans from rabbit articular chondrocytes,” European Journal of Pharmacology, vol. 401, no. 3, pp. 429–436, 2000. View at Publisher · View at Google Scholar · View at Scopus
  174. S. A. Syggelos, E. Giannopoulou, P. A. Gouvousis, A. P. Andonopoulos, A. J. Aletras, and E. Panagiotopoulos, “In vitro effects of non-steroidal anti-inflammatory drugs on cytokine, prostanoid and matrix metalloproteinase production by interface membranes from loose hip or knee endoprostheses,” Osteoarthritis and Cartilage, vol. 15, no. 5, pp. 531–542, 2007. View at Publisher · View at Google Scholar · View at Scopus
  175. Y. Ishimi, C. Miyaura, C. H. Jin et al., “IL-6 is produced by osteoblasts and induces bone resorption,” Journal of Immunology, vol. 145, no. 10, pp. 3297–3303, 1990. View at Scopus
  176. N. Kurihara, D. Bertolini, T. Suda, Y. Akiyama, and G. D. Roodman, “IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release,” Journal of Immunology, vol. 144, no. 11, pp. 4226–4230, 1990. View at Scopus
  177. U. H. Lerner and A. Ohlin, “Tumor necrosis factors α and β can stimulate bone resorption in cultured mouse calvariae by a prostaglandin-independent mechanism,” Journal of Bone and Mineral Research, vol. 8, no. 2, pp. 147–155, 1993. View at Scopus
  178. J. H. Herman, W. G. Sowder, and E. V. Hess, “Nonsteroidal antiinflammatory drug modulation of prosthesis pseudomembrane induced bone resorption,” Journal of Rheumatology, vol. 21, no. 2, pp. 338–343, 1994. View at Scopus